NCT00338117View on ClinicalTrials.gov

Safety and Efficacy of High Dose, Rapid Titration Galantamine in Patients With Alzheimer's Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

554

Participants

Timeline

Start Date

August 31, 1995

Study Completion Date

May 31, 1997

Conditions
Alzheimer's DiseaseDementia
Interventions
DRUG

Galantamine hydrobromide

Sponsors

Collaborators (1)

Shire
All Listed Sponsors
collaborator

Shire

INDUSTRY

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY